What are Analysts opinions on FibroGen, Inc(NASDAQ:FGEN): Surface Oncology, Inc.(NASDAQ:SURF)

0
1

FibroGen, Inc (FGEN) will report its next earnings on Mar 02 AMC. The company reported the earnings of $-1.12/Share in the last quarter where the estimated EPS by analysts was $-0.59/share. The difference between the expected and actual EPS was $-0.53/share, which represents an Earnings surprise of -89.8%.

Many analysts are providing their Estimated Earnings analysis for FibroGen, Inc and for the current quarter 8 analysts have projected that the stock could give an Average Earnings estimate of $-0.45/share. These analysts have also projected a Low Estimate of $-0.93/share and a High Estimate of $-0.08/share.

In case of Revenue Estimates, 7 analysts have provided their consensus Average Revenue Estimates for FibroGen, Inc as 70.7 Million. According to these analysts, the Low Revenue Estimate for FibroGen, Inc is 23 Million and the High Revenue Estimate is 92.6 Million. The company had Year Ago Sales of 17.88 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for FGEN to be 24.5%. They are projecting Next Quarter growth of -140.48%. For the next 5 years, FibroGen, Inc is expecting Growth of 17.68% per annum, whereas in the past 5 years the growth was -25.84% per annum.

The Relative Volume of the company is 1.37 and Average Volume (3 months) is 698.09 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -8.9%. The Return on Equity (ROE) value stands at -13.8%. While it’s Return on Investment (ROI) value is -15.3%.

While looking at the Stock’s Performance, FibroGen, Inc currently shows a Weekly Performance of 35.41%, where Monthly Performance is -26.56%, Quarterly performance is -29.76%, 6 Months performance is -17.13% and yearly performance percentage is -42.05%. Year to Date performance value (YTD perf) value is -26.44%. The Stock currently has a Weekly Volatility of 12.54% and Monthly Volatility of 10.61%.

Surface Oncology, Inc. (SURF) will report its next earnings on Mar 05. The company reported the earnings of $-0.57/Share in the last quarter where the estimated EPS by analysts was $-0.58/share. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 1.7%.

Many analysts are providing their Estimated Earnings analysis for Surface Oncology, Inc. and for the current quarter 3 analysts have projected that the stock could give an Average Earnings estimate of $0.43/share. These analysts have also projected a Low Estimate of $-0.39/share and a High Estimate of $0.88/share.

These analysts also forecasted Growth Estimates for the Current Quarter for SURF to be 233.3%. They are projecting Next Quarter growth of 0%. For the next 5 years, Surface Oncology, Inc. is expecting Growth of -58.89% per annum, whereas in the past 5 years the growth was 31.47% per annum.

Some buy side analysts are also providing their Analysis on Surface Oncology, Inc., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

The Relative Volume of the company is 0.83 and Average Volume (3 months) is 162.79 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -36.8%. The Return on Equity (ROE) value stands at -70.6%. While it’s Return on Investment (ROI) value is -88.7%.

While looking at the Stock’s Performance, Surface Oncology, Inc. currently shows a Weekly Performance of 14.58%, where Monthly Performance is -51.18%, Quarterly performance is 5.1%, 6 Months performance is -11.29% and yearly performance percentage is -64.59%. Year to Date performance value (YTD perf) value is -12.23%. The Stock currently has a Weekly Volatility of 15.14% and Monthly Volatility of 15.96%.

SHARE